Xiong CY - Search Results

1

Characterization of site-specific ScFv PEGylation for tumor-targeting pharmaceuticals.

Natarajan A, Xiong CY, Albrecht H, DeNardo GL, DeNardo SJ. Natarajan A, et al. Among authors: xiong cy. Bioconjug Chem. 2005 Jan-Feb;16(1):113-21. doi: 10.1021/bc0498121. Bioconjug Chem. 2005. PMID: 15656582

2

Production of soluble ScFvs with C-terminal-free thiol for site-specific conjugation or stable dimeric ScFvs on demand.

Albrecht H, Burke PA, Natarajan A, Xiong CY, Kalicinsky M, DeNardo GL, DeNardo SJ. Albrecht H, et al. Among authors: xiong cy. Bioconjug Chem. 2004 Jan-Feb;15(1):16-26. doi: 10.1021/bc030018+. Bioconjug Chem. 2004. PMID: 14733579

3

Development of tumor targeting anti-MUC-1 multimer: effects of di-scFv unpaired cysteine location on PEGylation and tumor binding.

Xiong CY, Natarajan A, Shi XB, Denardo GL, Denardo SJ. Xiong CY, et al. Protein Eng Des Sel. 2006 Aug;19(8):359-67. doi: 10.1093/protein/gzl020. Epub 2006 Jun 7. Protein Eng Des Sel. 2006. PMID: 16760193

4

Construction of di-scFv through a trivalent alkyne-azide 1,3-dipolar cycloaddition.

Natarajan A, Du W, Xiong CY, DeNardo GL, DeNardo SJ, Gervay-Hague J. Natarajan A, et al. Among authors: xiong cy. Chem Commun (Camb). 2007 Feb 21;(7):695-7. doi: 10.1039/b611636a. Epub 2006 Nov 28. Chem Commun (Camb). 2007. PMID: 17392953

5

Development of multivalent radioimmunonanoparticles for cancer imaging and therapy.

Natarajan A, Xiong CY, Gruettner C, DeNardo GL, DeNardo SJ. Natarajan A, et al. Among authors: xiong cy. Cancer Biother Radiopharm. 2008 Feb;23(1):82-91. doi: 10.1089/cbr.2007.0410. Cancer Biother Radiopharm. 2008. PMID: 18298332

6

Labeling monoclonal antibodies with 90yttrium- and 111indium-DOTA chelates: a simple and efficient method.

Li M, Meares CF, Zhong GR, Miers L, Xiong CY, DeNardo SJ. Li M, et al. Among authors: xiong cy. Bioconjug Chem. 1994 Mar-Apr;5(2):101-4. doi: 10.1021/bc00026a001. Bioconjug Chem. 1994. PMID: 8031871

7

Antibody phage libraries for the next generation of tumor targeting radioimmunotherapeutics.

DeNardo SJ, DeNardo GL, DeNardo DG, Xiong CY, Shi XB, Winthrop MD, Kroger LA, Carter P. DeNardo SJ, et al. Among authors: xiong cy. Clin Cancer Res. 1999 Oct;5(10 Suppl):3213s-3218s. Clin Cancer Res. 1999. PMID: 10541366

8

Anti-HLA-DR/anti-DOTA diabody construction in a modular gene design platform: bispecific antibodies for pretargeted radioimmunotherapy.

DeNardo DG, Xiong CY, Shi XB, DeNardo GL, DeNardo SJ. DeNardo DG, et al. Among authors: xiong cy. Cancer Biother Radiopharm. 2001 Dec;16(6):525-35. doi: 10.1089/10849780152752128. Cancer Biother Radiopharm. 2001. PMID: 11789029

9

Effect of 67Cu-2IT-BAT-Lym-1 therapy on BCL-2 gene and protein expression in a lymphoma mouse model.

Kroger LA, DeNardo SJ, DeNardo GL, Xiong CY, Winthrop MD, Gumerlock PH. Kroger LA, et al. Among authors: xiong cy. Clin Cancer Res. 1999 Oct;5(10 Suppl):3010s-3014s. Clin Cancer Res. 1999. PMID: 10541336

10

Kroger LA, DeNardo GL, Gumerlock PH, Xiong CY, Winthrop MD, Shi XB, Mack PC, Leshchinsky T, DeNardo SJ. Kroger LA, et al. Among authors: xiong cy. Cancer Biother Radiopharm. 2001 Jun;16(3):213-25. doi: 10.1089/10849780152389401. Cancer Biother Radiopharm. 2001. PMID: 11471486

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

50 results

Search Page

Filters